Asset acquisitions.

No definition available.

Name:	mirm_AssetAcquisitionsLineItems
Namespace Prefix:	mirm_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Clinical development and regulatory milestone payments payable.

+ References

No definition available.

+ Details

Name:	mirm_ClinicalDevelopmentAndRegulatoryMilestonePaymentsPayable
Namespace Prefix:	mirm_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Clinical development and regulatory milestone payments payable upon commercialization.

+ References

No definition available.

+ Details

Name:	mirm_ClinicalDevelopmentAndRegulatoryMilestonePaymentsPayableUponCommercialization
Namespace Prefix:	mirm_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Clinical development and regulatory milestone payments payable upon initiation.

+ References

No definition available.

+ Details

Name:	mirm_ClinicalDevelopmentAndRegulatoryMilestonePaymentsPayableUponInitiation
Namespace Prefix:	mirm_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Clinical development and regulatory milestone payments payable upon regulatory approval.

+ References

No definition available.

+ Details

Name:	mirm_ClinicalDevelopmentAndRegulatoryMilestonePaymentsPayableUponRegulatoryApproval
Namespace Prefix:	mirm_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Collaborative Arrangement, Rights and Obligations, Maximum Aggregate Milestone Payments

+ References

No definition available.

+ Details

Name:	mirm_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments
Namespace Prefix:	mirm_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Development or regulatory milestones incurred

+ References

No definition available.

+ Details

Name:	mirm_DevelopmentOrRegulatoryMilestonesIncurred
Namespace Prefix:	mirm_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

License agreement milestone amount payable.

+ References

No definition available.

+ Details

Name:	mirm_LicenseAgreementMilestoneAmountPayable
Namespace Prefix:	mirm_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Milestone payment payable upon achievement of product sales.

+ References

No definition available.

+ Details

Name:	mirm_MilestonePaymentPayableUponAchievementOfProductSales
Namespace Prefix:	mirm_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Number of product candidates.

+ References

No definition available.

+ Details

Name:	mirm_NumberOfProductCandidates
Namespace Prefix:	mirm_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Payments For Achievement Of Various Clinical Development, Regulatory And Commercial Milestones

+ References

No definition available.

+ Details

Name:	mirm_PaymentsAndAccrualsForAchievementOfVariousClinicalDevelopmentRegulatoryAndCommercialMilestones
Namespace Prefix:	mirm_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Royalty payment obligations period.

+ References

No definition available.

+ Details

Name:	mirm_RoyaltyPaymentObligationsPeriod
Namespace Prefix:	mirm_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479581/805-30-50-1

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-13

+ Details

Name:	us-gaap_PaymentsToAcquireBusinessesGross
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 13
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-13

+ Details

Name:	us-gaap_PaymentsToAcquireIntangibleAssets
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mirm_ShireInternationalGmbHMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=mirm_LivmarliMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=mirm_AssetPurchaseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BusinessAcquisitionAxis=mirm_BileAcidMedicinesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mirm_TravereTherapeuticsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=mirm_AssignmentAndLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=mirm_VolixibatMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=mirm_EnthorinTherapeuticsLLCAndDartNeuroscienceLLCMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=mirm_SatiogenPharmaceuticalsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=mirm_AssignedLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=mirm_SanofiAventisDeutschlandGmbHMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Asset Acquisitions (Details)		1 Months Ended		3 Months Ended
Asset Acquisitions (Details)	Aug. 31, 2023 USD ($)	Oct. 31, 2024 USD ($)	Nov. 30, 2018 USD ($) productCandidate	Mar. 31, 2025 USD ($)	Mar. 31, 2024 USD ($)
Shire \| Livmarli
Asset Acquisitions [Line Items]
Development or regulatory milestones incurred				$ 0	$ 0
Asset Purchase Agreement \| Bile Acid Medicines \| Travere Therapeutics, Inc.
Asset Acquisitions [Line Items]
Payments for acquisition	$ 210,400,000
Product sales milestone payments, payable	$ 235,000,000.0
Shire Agreement \| Livmarli
Asset Acquisitions [Line Items]
Milestones accrued				5,000,000.0	$ 10,000,000.0
Shire Agreement \| Shire
Asset Acquisitions [Line Items]
Product sales milestone payments, payable			$ 30,000,000.0
Number of product candidates \| productCandidate			2
Shire Agreement \| Shire \| Livmarli
Asset Acquisitions [Line Items]
Milestone payments, payable			$ 109,500,000
Milestone payments, payable upon approval			25,000,000.0
Shire Agreement \| Shire \| Volixibat
Asset Acquisitions [Line Items]
Milestone payments, payable upon commercialization			30,000,000.0
Payments and accruals for achievement of various clinical development, regulatory and commercial milestones				91,500,000
Enthorin Therapeutics, LLC and Dart Neuroscience LLC \| Collaborative Arrangement, Transaction with Party to Collaborative Arrangement
Asset Acquisitions [Line Items]
Payments for intangible assets		$ 7,500,000
Additional payments to acquire intangible assets		$ 217,500,000
Satiogen Pharmaceuticals, Inc. \| Assigned License Agreement
Asset Acquisitions [Line Items]
Milestone payments, payable			10,500,000
Milestone payments, payable upon approval			5,000,000.0
Milestone payments, payable upon commercialization			5,000,000.0
Milestone payments, payable upon initiation			500,000
Sanofi-Aventis Deutschland GmbH \| Assigned License Agreement
Asset Acquisitions [Line Items]
Milestone payments, payable			$ 36,000,000.0
Milestones accrued				$ 0
Royalty obligations payment period			10 years